1. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy
- Author
-
Dawn J Storey, L C Frew, Duncan B. McLaren, M A Atkinson, Isabella Butcher, Michael Sharpe, and John F. Smyth
- Subjects
Male ,medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,Antineoplastic Agents, Hormonal ,Urology ,Population ,Pain ,Anxiety ,lcsh:RC870-923 ,Hospital Anxiety and Depression Scale ,Gonadotropin-Releasing Hormone ,Androgen deprivation therapy ,Prostate cancer ,Internal medicine ,Prevalence ,medicine ,Humans ,Brief Pain Inventory ,education ,Fatigue ,Depression (differential diagnoses) ,Aged ,Aged, 80 and over ,education.field_of_study ,Depression ,business.industry ,Prostatic Neoplasms ,Hematology ,Odds ratio ,Middle Aged ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Cross-Sectional Studies ,Logistic Models ,Oncology ,Multivariate Analysis ,Quality of Life ,Physical therapy ,International Prostate Symptom Score ,Self Report ,medicine.symptom ,business - Abstract
Background: The purpose of the study was to determine the prevalence and associations of clinically relevant fatigue (CRF) in men with biochemically controlled prostate cancer on long-term androgen deprivation therapy (ADT). Patients and methods: One hundred and ninety-eight men were surveyed and the prevalence of CRF (Brief Fatigue Inventory score >3) determined. Associations with other measures (Hospital Anxiety and Depression Scale; International Prostate Symptom Score; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Brief Pain Inventory worst pain; clinical and demographic information) were explored in univariate and multivariate analyses. Results: Eight-one per cent (160 of 198) of questionnaires were analysable. CRF prevalence was 43% (68 of 160). CRF associations included moderate/severe urinary symptoms, anxiety and medical co-morbidities; the strongest associations were depression [odds ratio (OR) 9.8, 95% confidence interval (CI) 4.3-22.8] and pain (OR 9.2, 95% CI 4.0-21.5). After controlling for other factors, the independent associations were depression (OR 4.7, 95% CI 1.6-14.0) and pain (OR 3.1, 95% CI 1.0-8.9). There was no association with age, disease burden or treatment duration. Conclusions: Two-fifths of men with biochemically controlled prostate cancer on long-term ADT report CRF that interferes with function. Management aimed at improving CRF should address depression and pain. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
- Published
- 2011